Illumina 配当と自社株買い

配当金基準チェック /16

Illumina配当を支払う会社であり、現在の利回りは2.36%です。

主要情報

2.4%

配当利回り

0.3%

バイバック利回り

総株主利回り	0.3%
将来の配当利回り	0%
配当成長	n/a
次回配当支払日	n/a
配当落ち日	n/a
一株当たり配当金	n/a
配当性向	n/a

最近の配当と自社株買いの更新

更新なし

Recent updates

Illumina: Strengthening Competitive Position, Relevance And A Very Compelling Valuation

Jul 23

Illumina, Inc.'s (NASDAQ:ILMN) Share Price Could Signal Some Risk

Jul 01

Illumina: Marriage Made In Hell Is (Finally) Over - Assessing Impact Of GRAIL Spin-Out

Jun 28

Should You Investigate Illumina, Inc. (NASDAQ:ILMN) At US$106?

May 26

Illumina: Expect A Slow Rebound

May 07

Calculating The Fair Value Of Illumina, Inc. (NASDAQ:ILMN)

Apr 26

Revenues Not Telling The Story For Illumina, Inc. (NASDAQ:ILMN)

Mar 20

Illumina: Stagnant Revenues And Shrinking Margins Amidst Rising Competition

Feb 23

Would Illumina (NASDAQ:ILMN) Be Better Off With Less Debt?

Jan 26

Illumina: Volatility Galore, But Not Much Prospect Of Progress In 2024

Jan 19

Investors Appear Satisfied With Illumina, Inc.'s (NASDAQ:ILMN) Prospects As Shares Rocket 40%

Dec 21

Is Illumina, Inc. (NASDAQ:ILMN) Potentially Undervalued?

Dec 03

Would Illumina (NASDAQ:ILMN) Be Better Off With Less Debt?

Oct 24

Is There An Opportunity With Illumina, Inc.'s (NASDAQ:ILMN) 40% Undervaluation?

Oct 03

At US$167, Is Illumina, Inc. (NASDAQ:ILMN) Worth Looking At Closely?

Aug 22

The Big Trends: New Frontiers in Healthcare

Jul 13

Estimating The Intrinsic Value Of Illumina, Inc. (NASDAQ:ILMN)

Jul 03

Illumina (NASDAQ:ILMN) Is Carrying A Fair Bit Of Debt

Jun 13

Is It Time To Consider Buying Illumina, Inc. (NASDAQ:ILMN)?

Apr 12

Is Illumina (NASDAQ:ILMN) Using Too Much Debt?

Mar 14

決済の安定と成長

配当データの取得

安定した配当: ILMNの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。

増加する配当: ILMNの配当金が増加しているかどうかを判断するにはデータが不十分です。

配当利回り対市場

Illumina 配当利回り対市場

ILMN 配当利回りは市場と比べてどうか？
セグメント	配当利回り
会社 (ILMN)	2.4%
市場下位25% (US)	1.4%
市場トップ25% (US)	4.3%
業界平均 (Life Sciences)	0.5%
アナリスト予想 (ILMN) (最長3年)	0%

注目すべき配当: ILMNの配当金 ( 2.36% ) はUS市場の配当金支払者の下位 25% ( 1.38% ) よりも高くなっています。

高配当: ILMNの配当金 ( 2.36% ) はUS市場の配当金支払者の上位 25% ( 4.32% ) と比較すると低いです。

株主への利益配当

収益カバレッジ: ILMNの配当性向を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。

株主配当金

キャッシュフローカバレッジ: ILMNが配当金を報告していないため、配当金の持続可能性を計算できません。

Illumina 配当と自社株買い

配当金 基準チェック /16

主要情報

最近の配当と自社株買いの更新

Recent updates

Illumina, Inc. Announces Expansion of TruSight Oncology Portfolio

Illumina, Inc. Lowers Revenue Guidance for the Full Year 2024

Illumina: Q3 Confirms Improving Fundamentals

Illumina, Inc. Lowers Revenue Guidance for the Full Year 2024

Illumina to Preview Newest Innovations in NGS and Multiomic Technologies At the American Society of Human Genetics Annual Meeting

We Think Illumina (NASDAQ:ILMN) Can Stay On Top Of Its Debt

Illumina, Inc. Introduces the MiSeq i100 Series

Illumina, Inc. to Report Q3, 2024 Results on Nov 04, 2024

Illumina, Inc. Announces Executive Changes

European Court of Justice Rules in Favor of Illumina, Inc. in Relation to Relation to the European Commission's Acquisition of GRAIL

Illumina, Inc. Announces Food and Drug Administration Approval for Its Cancer Biomarker Test with Two Companion Diagnostics to Rapidly Match Patients to Targeted Therapies

Illumina Sees The Light: GRAIL Is Gone, Focus Restored (Rating Upgrade)

Consensus EPS estimates upgraded to US$9.60 loss

Now 23% overvalued after recent price rise

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Illumina, Inc. Announces Impairment Charges for the Second Quarter Ended June 30, 2024

Illumina Launches New Oncology Menu for NovaSeq X Series Customers

Consensus EPS estimates fall from profit to US$1.71 loss

Illumina: Strengthening Competitive Position, Relevance And A Very Compelling Valuation

Illumina, Inc. (NasdaqGS:ILMN) acquired Fluent BioSciences Inc.

Illumina, Inc. (NasdaqGS:ILMN) acquired Fluent BioSciences Inc.

Illumina, Inc.'s (NASDAQ:ILMN) Share Price Could Signal Some Risk

Illumina: Marriage Made In Hell Is (Finally) Over - Assessing Impact Of GRAIL Spin-Out

Consensus EPS estimates upgraded to US$0.93 loss

Illumina, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Illumina, Inc.(NasdaqGS:ILMN) dropped from S&P 500 Value

Now 24% overvalued

Illumina Launches Latest Chemistry Across Most Popular Mid-Throughput Sequencers, Enabling Higher Quality and Greater Speed for Customers at Lower Cost

Should You Investigate Illumina, Inc. (NASDAQ:ILMN) At US$106?

Illumina, Inc. Appoints Anna Richo to its Board of Directors

Now 22% overvalued

Illumina: Expect A Slow Rebound

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Illumina, Inc. Reaffirms Earnings Guidance for the Fiscal Year 2024

Calculating The Fair Value Of Illumina, Inc. (NASDAQ:ILMN)

Consensus EPS estimates fall by 25%

Illumina, Inc. Announces Chief Financial Officer Changes

Illumina, Inc. to Report Q1, 2024 Results on May 02, 2024

Consensus EPS estimates upgraded to US$0.56 loss

Revenues Not Telling The Story For Illumina, Inc. (NASDAQ:ILMN)

CEO & Director recently bought US$992k worth of stock

Illumina: Stagnant Revenues And Shrinking Margins Amidst Rising Competition

Consensus EPS estimates fall by 64%

Consensus EPS estimates upgraded to US$0.41 loss, revenue downgraded

Full year 2023 earnings: EPS misses analyst expectations

Illumina, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Would Illumina (NASDAQ:ILMN) Be Better Off With Less Debt?

Illumina: Volatility Galore, But Not Much Prospect Of Progress In 2024

Illumina, Inc. to Report Q4, 2023 Results on Feb 08, 2024

Pomerantz LLP Files a Class Action Lawsuit Against Illumina, Inc

Investors Appear Satisfied With Illumina, Inc.'s (NASDAQ:ILMN) Prospects As Shares Rocket 40%

Carl C. Icahn Releases Open Letter to Stockholders of Illumina, Inc

Now 20% undervalued after recent price drop

Hagens Berman Encourages Illumina Investors with Losses to Contact Firm’s Attorneys

Is Illumina, Inc. (NASDAQ:ILMN) Potentially Undervalued?

Glancy Prongay & Murray LLP Files Securities Fraud Lawsuit Against Illumina, Inc

Price target decreased by 15% to US$168

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Carl Icahn Accuses Board and Ex-CEO of Illumina Inc

Would Illumina (NASDAQ:ILMN) Be Better Off With Less Debt?

Carl Icahn Sues Illumina Inc’s Board for Violating Fiduciary Duties

Price target decreased by 9.4% to US$203

EU Orders Illumina to Sell Cancer Testing Firm Grail

Illumina, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Is There An Opportunity With Illumina, Inc.'s (NASDAQ:ILMN) 40% Undervaluation?

Illumina, Ventures Announces Appointment of Mara Aspinall, MBA as Partner of Investment Team

Illumina, Inc. Announces Chief Executive Officer Changes

At US$167, Is Illumina, Inc. (NASDAQ:ILMN) Worth Looking At Closely?

Price target decreased by 7.0% to US$224

Second quarter 2023 earnings: EPS misses analyst expectations

Illumina, Inc. Provides Consolidated Earnings Guidance for the Year 2023

Guardant Resolves Pending Litigation with Illumina and Enters into New Agreement to Advance Long-Term Commercial Partnership and Cancer Research

Illumina, Inc. to Report Q2, 2023 Results on Aug 09, 2023

The Big Trends: New Frontiers in Healthcare

Illumina DRAGEN™ 4.2 Delivers Most Accurate and Comprehensive Coverage of the Genome, Powering Greater Applications and Discovery

配当金基準チェック /16